Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001649553-25-000209
Filing Date
2025-11-18
Accepted
2025-11-18 11:53:37
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9948
2 LIMITED POWER OF ATTORNEY sc13g_ex24.htm EX-24 2382
3 JOINT FILING AGREEMENT slrx_sc13g-ex99.htm EX-99 1715
  Complete submission text file 0001649553-25-000209.txt   15857
Mailing Address 2450 HOLCOMBE BLVD SUITE J-608 HOUSTON TX 77021
Business Address 2450 HOLCOMBE BLVD SUITE J-608 HOUSTON TX 77021 346-772-0346
Salarius Pharmaceuticals, Inc. (Subject) CIK: 0001615219 (see all company filings)

EIN.: 465087339 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-88731 | Film No.: 251493451
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address P.O. BOX 309 UGLAND HOUSE GRAND CAYMAN E9 KY1-1104
Business Address P.O. BOX 309 UGLAND HOUSE GRAND CAYMAN E9 KY1-1104 345-949-8080
CVI Investments, Inc. (Filed by) CIK: 0001649553 (see all company filings)

EIN.: 981253664 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13G